Clinical trials
HER2-positive Metastatic Breast Cancer clinical trials
Below are recruiting her2-positive metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 165 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07065435RecruitingPhase 2
RC48 with Avastin or Pyrotinib for HER2+ breast cancer after T-DXd
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
Nanjing, JiangsuAges 18–75 - NCT07066917Recruiting
Breast cancer treatment response study
This study looks at how well newer treatments work for advanced or metastatic breast cancer and why some people respond better than others. It is for anyone with HR-positive, HER2-positive/low, or triple-negative breast cancer who has started at least one treatment cycle.
AthensAges 18 years+ - NCT07073755Recruiting
Study of next treatments after targeted therapy resistance for advanced breast cancer
This study looks at what happens when people with advanced breast cancer switch to a new treatment after their cancer becomes resistant to targeted therapies like CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd. Researchers want to understand which next treatments work best in real life.
Changsha, HunanAges 18 years+ - NCT07081555RecruitingPhase 1
Testing a new radioactive drug for HER2-positive advanced breast cancer
This trial tests a new radioactive drug, [177Lu]Lu-ABY-271, to see how safe it is and where it goes in the body. It is for people with HER2-positive breast cancer that has spread and cannot be removed by surgery.
GothenburgAges 18 years+ - NCT07162675Recruiting
Step count and treatment response in breast cancer patients
This study looks at how your daily step count, measured by a smartwatch, relates to how well your breast cancer responds to treatment before surgery. It may help show if being more active during chemotherapy leads to better outcomes.
Ankara, YenimahalleAges 18 years+ - NCT07166185Recruiting
Targeted therapy before surgery for HER2+ breast cancer
This trial tests a combination of two targeted drugs (trastuzumab and pertuzumab) given as a shot under the skin before surgery for women with a specific type of breast cancer called HER2-positive. The goal is to see if this treatment works well for women in Algeria.
BlidaAges 19 years+ - NCT07182721RecruitingPhase 2
Study of SKB264 plus Inetetamab for advanced HER2+ breast cancer after T-DXd
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT07220135RecruitingPhase 2
Comparing two drug combos before surgery for HER2+ breast cancer
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
Fairway, KansasAges 18 years+ - NCT07233928Recruiting
Breast cancer protein study in different subtypes
This trial takes a close look at the proteins inside breast cancer cells, using samples from people with different subtypes. It aims to better understand how each type behaves, which could help guide future treatments.
ToulouseAges 18 years+ - NCT07294508RecruitingPhase 2/Phase 3
Testing a new drug combo for HER2-positive advanced breast cancer
This trial tests two study drugs, HLX22 and HLX87, together for people with HER2-positive breast cancer that has spread or come back. It may be an option if you haven't yet had chemotherapy or HER2-targeted therapy for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07371585RecruitingPhase 2
Trastuzumab Deruxtecan for first-line HER2-positive advanced breast cancer
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
VillejuifAges 18 years+ - NCT07376174Recruiting
HER2-positive breast cancer and dual-target therapy study
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Jinan, ShandongAges 18 years+ - NCT02422641RecruitingPhase 2
High-dose methotrexate for breast cancer in the brain lining
This Phase 2 trial tests whether giving high-dose methotrexate into the bloodstream can help treat breast cancer that has spread to the thin lining covering the brain and spinal cord. It may help reduce cancer in the leptomeningeal (brain-lining) area and control symptoms.
Baltimore, MarylandAges 18 years+ - NCT07455188Recruiting
Switching targeted therapies for advanced HER2-positive breast cancer
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
Zhejiang, HangzhouAges 18 years+ - NCT07459673RecruitingPhase 2
HER2-positive breast cancer trial using ctDNA to guide treatment
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
Basking Ridge, New JerseyAges 18 years+ - NCT07486089RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for advanced breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
Shenzhen, GuangdongAges 18–75 - NCT07503717Recruiting
Brain scan surveillance in HER2-positive metastatic breast cancer
This study tests whether regular brain scans (surveillance) help spot brain metastases early in people with HER2-positive breast cancer that has spread to other parts of the body. Participation involves being randomly assigned to either routine brain scans or no extra scans to see which approach is better.
BeaumontAges 18 years+ - NCT07510802RecruitingPhase 1/Phase 2
CAR-NK cells for advanced HER2+ or triple-negative breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
Shenzhen, GuangdongAges 18–75 - NCT07542496Recruiting
Real-world study of breast cancer treatment with pertuzumab biosimilar
This study observes how a biosimilar version of pertuzumab (a targeted breast cancer drug) works in real-world patients. Researchers will track outcomes in patients receiving this drug either before surgery or as a first treatment for advanced breast cancer.
AlgiersAges 19 years+ - NCT07610720RecruitingPhase 2
Dalpiciclib With Anti-HER2 and Hormone Therapy for Advanced Breast Cancer
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
Guangdong, GUANGZHOUAges 18–75 - NCT07666555RecruitingPhase 2
Culmerciclib rechallenge for HR+ HER2- breast cancer
This trial tests a new drug called Culmerciclib for women with advanced HR-positive, HER2-negative breast cancer that has stopped responding to a CDK4/6 inhibitor with hormone therapy. The goal is to see if giving this drug again can help when other treatments no longer work.
ShanghaiAges 18–75 - NCT07292571Enrolling by invitationPhase 2
Tracing breast cancer HER2 with a special scan
This study uses a radioactive tracer to see how much HER2 protein is on your breast cancer cells. The scan may help doctors understand the type of HER2 you have and choose the best treatment.
TomskAges 18–80 - NCT07023861Enrolling by invitationEarly Phase 1
New imaging test for HER2-positive cancers
This trial tests a new imaging method that uses a radioactive tracer to find HER2-positive cancer cells in the body. It may help doctors see tumors more clearly in people with stomach, breast, or bladder cancer.
Wuxi, JiangsuAges 15–75 - NCT06843681Enrolling by invitationPhase 2
Trastuzumab and Chemo Before Surgery for HER2-Positive DCIS
This trial tests giving trastuzumab (a targeted drug) plus a chemotherapy drug called a taxane before surgery for women with HER2-positive ductal carcinoma in situ (DCIS), an early form of breast cancer. The goal is to see if this combination can shrink or eliminate the cancer before surgery.
Guangzhou, GuangdongAges 18–70
Hear when a new HER2-positive Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2-positive metastatic breast cancer?
- Yes. Clin2 currently lists 165 recruiting her2-positive metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2-positive metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2-positive metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- HER2-positive Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HER2-positive Advanced Breast Cancer
- HR-positive, HER2-negative Advanced Breast Cancer
- HER2-positive Early Breast Cancer
- HR Positive/HER2 Low Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.